mTOR complex 2 stabilizes Mcl-1 protein by suppressing its glycogen synthase kinase 3-dependent and SCF-FBXW7-mediated degradation

Molecular and Cellular Biology

Volumn 35, Issue 13, 2015, Pages 2344-2355

  Koo, Junghui ^a   Yue, Ping ^a   Deng, Xingming ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; AZD 8055; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PROTEASOME; PROTEIN; PROTEIN MCL 1; SAPANISERTIB; SIN1 PROTEIN; TORIN 1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; EMBRYO; ENZYME INHIBITION; EXPERIMENTAL NEOPLASM; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; UBIQUITINATION; CELL PROLIFERATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

RAPTORES;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LUNG; LUNG NEOPLASMS; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN STABILITY; PROTEOLYSIS; RNA, MESSENGER; SKP CULLIN F-BOX PROTEIN LIGASES; TOR SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84930858062     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01525-14     Document Type: Article

References (31)

1. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22. http://dx.doi.org/10.1016/j.ccr.2007.05.008.
2. Oh WJ, Jacinto E. 2011. mTOR complex 2 signaling and functions. Cell Cycle 10:2305-2316. http://dx.doi.org/10.4161/cc.10.14.16586.
3. Wang X, Sun SY. 2009. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 13:1193-1203. http://dx.doi.org/10.1517/14728220903225008.
4. Sun SY. 2013. Impact of genetic alterations on mTOR-targeted cancer therapy. Chin J Cancer 32:270-274. http://dx.doi.org/10.5732/cjc.013.10005.
5. Sun SY. 2013. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 340:1-8. http://dx.doi.org/10.1016/j.canlet.2013.06.017.
6. Zhang YJ, Duan Y, Zheng XF. 2011. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 16:325-331. http://dx.doi.org/10.1016/j.drudis.2011.02.008.
7. Thomas LW, Lam C, Edwards SW. 2010. Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981-2989. http://dx.doi.org/10.1016/j.febslet.2010.05.061.
8. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J. 2008. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853-10858. http://dx.doi.org/10.1073/pnas.0804821105.
9. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC. 2007. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27:4006-4017. http://dx.doi.org/10.1128/MCB.00620-06.
10. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. 2006. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21:749-760. http://dx.doi.org/10.1016/j.molcel.2006.02.009.
11. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJ, Leong KG, Dueber EC, Maecker H, Huang DC, Dixit VM. 2011. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471:110-114. http://dx.doi.org/10.1038/nature09779.
12. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, Xiao Y, Christie AL, Aster J, Settleman J, Gygi SP, Kung AL, Look T, Nakayama KI, DePinho RA, Wei W. 2011. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471:104-109. http://dx.doi.org/10.1038/nature09732.
13. Koo J, Yue P, Gal AA, Khuri FR, Sun SY. 2014. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res 74:2555-2568. http://dx.doi.org/10.1158/0008-5472.CAN-13-2946.
14. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. 2008. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68:7409-7418. http://dx.doi.org/10.1158/0008-5472.CAN-08-1522.
15. Zhao L, Yue P, Khuri FR, Sun SY. 2013. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res 73:1946-1957. http://dx.doi.org/10.1158/0008-5472.CAN-12-3710.
16. Ren H, Zhao L, Li Y, Yue P, Deng X, Owonikoko TK, Chen M, Khuri FR, Sun SY. 2013. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett 338:229-238. http://dx.doi.org/10.1016/j.canlet.2013.03.032.
17. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R. 1997. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57:4931-4939.
18. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. 2005. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052-7058. http://dx.doi.org/10.1158/0008-5472.CAN-05-0917.
19. Ren H, Koo J, Guan B, Yue P, Deng X, Chen M, Khuri FR, Sun SY. 2013. The E3 ubiquitin ligases beta-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Mol Cancer 12:146. http://dx.doi.org/10.1186/1476-4598-12-146.
20. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. 2012. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61. http://dx.doi.org/10.1038/nature10912.
21. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH, Wei W. 2012. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett 586:1409-1418. http://dx.doi.org/10.1016/j.febslet.2012.03.017.
22. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8:83-93. http://dx.doi.org/10.1038/nrc2290.
23. Gao D, Wan L, Inuzuka H, Berg AH, Tseng A, Zhai B, Shaik S, Bennett E, Tron AE, Gasser JA, Lau A, Gygi SP, Harper JW, DeCaprio JA, Toker A, Wei W. 2010. Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol Cell 39:797-808. http://dx.doi.org/10.1016/j.molcel.2010.08.016.
24. Guo Z, Zhou Y, Evers BM, Wang Q. 2012. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem Biophys Res Commun 418:426-432. http://dx.doi.org/10.1016/j.bbrc.2012.01.054.
25. Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, Izumiya M, Sakai G, Adachi M, Funakoshi S, Nakamura S, Hamamoto Y, Kanai T, Takaishi H, Kawakami Y, Hibi T. 2013. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 16:100-110. http://dx.doi.org/10.1007/s10120-012-0153-6.
26. Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G. 2014. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol 92:55-61. http://dx.doi.org/10.1016/j.bcp.2014.07.029.
27. Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S. 2013. Panmammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by downregulating Mcl-1 protein. J Biol Chem 288:35287-35296. http://dx.doi.org/10.1074/jbc. M113.495986.
28. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA. 2014. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 4:42-52. http://dx.doi.org/10.1158/2159-8290.CD-13-0315.
29. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769-776. http://dx.doi.org/10.1038/35096075.
30. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101. http://dx.doi.org/10.1126/science.1106148.
31. Perciavalle RM, Opferman JT. 2013. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol 23:22-29. http://dx.doi.org/10.1016/j.tcb.2012.08.011.